Industry Trends

Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials

By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore.  Read More




Site Solutions for All that Ails EDC



By Deb Borfitz

June 22, 2009 | In a recent issue of eCliniqua, investigative sites aired their frustrations with many of the e-clinical technologies embraced by study sponsors. They made particular note of technical deficiencies with electronic data capture (EDC) systems. But, as discussed below, they also offered some solid remedies for improving the situation.

Sponsors building electronic case report forms (eCRFs) in-house might want to start pre-populating data fields with information from subjects’ prior visits, says Diane Palmer, site administrator and clinical research coordinator at New London, Conn.-based Coastal Connecticut Research (CCR). Better yet, site personnel could enter study visit data on a single page.

The Holy Grail of eCRFs would be for the industry as a whole to come up with standards for data entry, she continues. For sites like CCR doing multiple studies, it’s difficult to remember company-specific requirements for inputting information. There are four alternatives for the date format alone: 5/26/2009, 26May2009, 26May09, or 5/26/09. Failure to follow data-entry rules results in automatically generated, time-consuming queries, which steals time from patient recruitment activities.

Palmer declares Phase Forward’s Inform EDC system “one of the best” and worthy of mimicking, including its online training module that includes a printed certificate of completion. Unfortunately, she adds, companies rarely accept the certificate as proof of training for subsequent studies using the same system. She can complete the online test in ten minutes because she knows the answers by heart. Ironically, being a speedy test-taker flags her as a potential cheater in the eyes of some sponsors.

EDC systems as a rule fail to provide the kind of information that could make life easier for sites, such as a study’s enrollment status, according to Richard Litov, director of Pedia Research in Owensboro, KY. Instead, they deliver the intelligence six weeks late via hardcopy newsletters. “Sponsors and CROs can see that information [electronically]. Why not us too?”

Similarly, adds Litov, central lab vendors continue to transmit lab values via fax. In an ideal world, sites would receive lab reports electronically, including a graphic display comparing current and previous lab values of a study subject so investigators don’t have to sift through paper charts to detect important changes. Doing so “would lead to better oversight and evaluation of safety.”

Litov says it would serve sponsors’ interests to involve at least a few sites in the technology acquisition process and then conduct post-study surveys to learn how well a chosen EDC system performs in the real world. “We’ve seen a sponsor switch to a different EDC system for each of three studies conducted in the same program.”

From the standpoint of consistency and accuracy, it would be advantageous for sponsors to provide a standard, study-specific template for source document forms rather than rely on each site to generate their own forms from scratch, especially since these forms mirror the CRFs that are already produced, says Litov. He estimates that Pedia Research donates between 5-20 hours of “secretarial work” per study to create the requisite forms. “Multiply that by 50 or more sites for a multi-center trial and that is a lot of wasted time diverting sites from starting up a study.”

Kelly Walker, chief operating officer at Research Across America (RAA) in Dallas, believes it is time EDC systems were incorporating user-friendly handwriting or voice recognition features. Knowing it could be a long wait, he has taken matters into his own hands by developing a single-data-entry system called DB Pharma, with a programmer familiar with Microsoft tools.

DB Pharma, run off a wireless tablet, utilizes handwriting recognition technology and immediately transmits data to a web host. But it only gets used on a few studies a year, when RAA is responsible for either all of the data capture or all of the data analysis. The system’s only downside, Walker says, is that it doesn’t accommodate doctors’ notoriously sloppy script.

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Life Science Webcasts & Podcasts

medidata podcast #8 Meeting Today’s Challenges in Clinical Trial Supply Management
Sponsored by: Medidata Solutions Worldwide  

Setting up and managing the clinical trial involves many complex procedures. Among the most challenging are planning and executing the logistics of the trial’s clinical supplies. This podcast focuses in depth on the following topics which trace current practices and future evolution of this crucial aspect of clinical trials:

  • Current practices in clinical trial logistics
  • Comparing advances in clinical supply practices to  other aspects of clinical trials 
  • Where current practices fall short of meeting the challenges
  • Trends and evolving improvements that may change the way logistics are conducted

Listen Now  


More Podcasts

Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 





Sponsored Links

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .